宜联生物宣布任命Bruce Chabner博士为资深战略顾问，以增强其全球临床开发实力

中国苏州、美国马萨诸塞州剑桥，2024年10月18日，苏州宜联生物医药有限公司（以下简称“宜联生物”），一家处于临床阶段的生物科技公司，今日宣布任命Bruce A. Chabner医学博士为资深战略顾问。Chabner博士在肿瘤医学方面的丰富专业知识将帮助宜联生物加强其下一代抗体偶联药物（ADC）管线的全球研发。

“非常荣幸欢迎Bruce Chabner博士的加入，”宜联生物首席执行官薛彤彤博士说，“Bruce是当今世界上最有经验的肿瘤医学家之一，他有着多年的丰富经验以及深刻的科学视野。Chabner博士的加入将帮助宜联的ADC管线推进至新的高度。这对宜联来说非常重要，因为我们的创新ADC管线正处于推向全球病患的关键时刻。”

Bruce A. Chabner博士是美国麻省总医院（Massachusetts General Hospital，MGH）癌症中心名誉临床主任、哈佛医学院教授。他毕业于耶鲁学院和哈佛医学院，曾在国家癌症研究所（National Cancer Institute，NCI）Vincent De Vita的指导下接受医学肿瘤学训练，并在耶鲁大学Joseph Bertino的生化药理学实验室进行研究。之后他于1971年回到NCI，1975年成为临床肿瘤学科主任，并从1982年到1995年担任NCI癌症治疗部门主任。在此期间，他负责了紫杉醇、顺铂等多款肿瘤药物的开发。1995年，他加入MGH并担任血液学和医学肿瘤学部门主任以及MGH癌症中心主任。在MGH任职的12年期间，他建立起了对非小细胞癌症等实体瘤的靶向药物开发起到关键作用的相关教职和研究项目。他是2000年成立的Dana Farber/哈佛癌症中心基金的创始科学委员之一，并自此牵头参与其治疗开发项目。他在过去的40年内牵头了多项肿瘤医学项目，并培养出了多位转化和临床医学研究学者。

宜联生物成立于2020年，是一家专注于开发创新型偶联药物的临床阶段生物科技公司。公司开发的新一代具有自主知识产权的肿瘤微环境可激活的新型毒素连接子平台技术（TMALIN®）可实现高DAR值高均一性的稳定偶联，有助于提高ADC药物在实体瘤适应症上的治疗窗。公司致力于以未满足的临床需求为目标，为全球肿瘤患者带来更好的治疗方案。宜联生物位于中国苏州，并在中国上海、美国波士顿建立研发分支机构。

MediLink Appoints Bruce Chabner, M.D., as Senior Strategic Advisor, Strengthening MediLink’s Global Clinical Development Capability

Suzhou, China and Cambridge, Massachusetts, USA, October 18th, 2024 - MediLink Therapeutics (Suzhou) Co., Ltd. ("MediLink"), a clinical-stage biotech company, today announces the appointment of Bruce Chabner, M.D., as Senior Strategic Advisor. Dr. Chabner will serve as a key Scientific Advisory Board member to the MediLink leadership team and bring his significant expertise in medical oncology to help strengthen MediLink’s global development efforts on its next-generation antibody drug conjugate pipelines.

“I am thrilled to welcome Dr. Bruce Chabner to our team,” said Dr Tony Tongtong Xue, CEO of MediLink. “Bruce is one of the most renowned oncologists in the world, and his decades of experience and profound scientific insights will undoubtedly propel our pipeline of innovative ADCs to new heights. Dr. Chabner's appointment comes at a pivotal time for MediLink as we strive to bring transformative therapies to global patients in need.

Bruce A. Chabner, M. D., is the Clinical Director, Emeritus, of the Massachusetts General Hospital (MGH) Cancer Center and a Professor of Medicine at Harvard Medical School. He is a graduate of Yale College and Harvard Medical School. Dr. Chabner trained in medical oncology under Vincent De Vita at the National Cancer Institute and in the biochemical pharmacology laboratory of Joseph Bertino at Yale, following which he returned to the National Cancer Institute in 1971, where he became the Director of the Clinical Oncology Program in 1975 and served as the Director of the NCI Division of Cancer Treatment from 1982 to 1995. In that capacity he was responsible for the development of paclitaxel, cisplatin, and a number of other cancer drugs. In 1995 he joined MGH as Chief of the Division of Hematology and Medical Oncology and Clinical Director of the MGH Cancer Center, in which capacity he served for 12 years, building a faculty and research program that was instrumental in developing targeted drugs for non-small cell cancer and other solid tumors. He was one of the founding scientific directors of the Dana Farber/Harvard Cancer Center grant, first awarded in 2000 and has since led and participated in its Developmental Therapeutics program. He led fellowship programs for medical oncology training for four decades and was responsible for the training of many of the current and past leaders in translational and clinical cancer research in the US and abroad.

MediLink Therapeutics, founded in 2020, is a clinical stage biotech company dedicated to developing conjugated drugs with global competitiveness. MediLink has developed its proprietary TMALIN® ADC technology platform, enabling the generation of homogeneous ADC with high drug-antibody ratio and improved therapeutic window for the treatment of solid tumors. MediLink aims to provide improved treatment options for global patients and address unmet medical needs. The company is headquartered in Suzhou, China and has established R&D sites in Shanghai, China and Boston, US.